406 related articles for article (PubMed ID: 20308544)
1. Targeting the protein prenyltransferases efficiently reduces tumor development in mice with K-RAS-induced lung cancer.
Liu M; Sjogren AK; Karlsson C; Ibrahim MX; Andersson KM; Olofsson FJ; Wahlstrom AM; Dalin M; Yu H; Chen Z; Yang SH; Young SG; Bergo MO
Proc Natl Acad Sci U S A; 2010 Apr; 107(14):6471-6. PubMed ID: 20308544
[TBL] [Abstract][Full Text] [Related]
2. Severe hepatocellular disease in mice lacking one or both CaaX prenyltransferases.
Yang SH; Chang SY; Tu Y; Lawson GW; Bergo MO; Fong LG; Young SG
J Lipid Res; 2012 Jan; 53(1):77-86. PubMed ID: 22039581
[TBL] [Abstract][Full Text] [Related]
3. GGTase-I deficiency reduces tumor formation and improves survival in mice with K-RAS-induced lung cancer.
Sjogren AK; Andersson KM; Liu M; Cutts BA; Karlsson C; Wahlstrom AM; Dalin M; Weinbaum C; Casey PJ; Tarkowski A; Swolin B; Young SG; Bergo MO
J Clin Invest; 2007 May; 117(5):1294-304. PubMed ID: 17476360
[TBL] [Abstract][Full Text] [Related]
4. Genetic evidence for in vivo cross-specificity of the CaaX-box protein prenyltransferases farnesyltransferase and geranylgeranyltransferase-I in Saccharomyces cerevisiae.
Trueblood CE; Ohya Y; Rine J
Mol Cell Biol; 1993 Jul; 13(7):4260-75. PubMed ID: 8321228
[TBL] [Abstract][Full Text] [Related]
5. Inactivation of farnesyltransferase and geranylgeranyltransferase I by caspase-3: cleavage of the common alpha subunit during apoptosis.
Kim KW; Chung HH; Chung CW; Kim IK; Miura M; Wang S; Zhu H; Moon KD; Rha GB; Park JH; Jo DG; Woo HN; Song YH; Kim BJ; Yuan J; Jung YK
Oncogene; 2001 Jan; 20(3):358-66. PubMed ID: 11313965
[TBL] [Abstract][Full Text] [Related]
6. Geranylgeranyltransferase I as a target for anti-cancer drugs.
Philips MR; Cox AD
J Clin Invest; 2007 May; 117(5):1223-5. PubMed ID: 17476354
[TBL] [Abstract][Full Text] [Related]
7. Peptide specificity of protein prenyltransferases is determined mainly by reactivity rather than binding affinity.
Hartman HL; Hicks KA; Fierke CA
Biochemistry; 2005 Nov; 44(46):15314-24. PubMed ID: 16285735
[TBL] [Abstract][Full Text] [Related]
8. Dominant negative alpha-subunit of FTase inhibits effects of insulin and IGF-I in MCF-7 cells.
Solomon CS; Goalstone ML
Biochem Biophys Res Commun; 2002 Mar; 291(3):458-65. PubMed ID: 11855811
[TBL] [Abstract][Full Text] [Related]
9. Insulin signals to prenyltransferases via the Shc branch of intracellular signaling.
Goalstone ML; Leitner JW; Berhanu P; Sharma PM; Olefsky JM; Draznin B
J Biol Chem; 2001 Apr; 276(16):12805-12. PubMed ID: 11278505
[TBL] [Abstract][Full Text] [Related]
10. [Inhibitors of isoprenylation of ras p21].
Yoshimatsu K
Gan To Kagaku Ryoho; 1997 Sep; 24(11):1495-502. PubMed ID: 9309147
[TBL] [Abstract][Full Text] [Related]
11. Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development.
Rowinsky EK; Windle JJ; Von Hoff DD
J Clin Oncol; 1999 Nov; 17(11):3631-52. PubMed ID: 10550163
[TBL] [Abstract][Full Text] [Related]
12. Protection against malignant conversion in SENCAR mouse skin by all trans retinoic acid: inhibition of the ras p21-processing enzyme farnesyltransferase and Ha-ras p21 membrane localization.
Agarwal R; Mohan RR; Ahmad N; Mukhtar H
Mol Carcinog; 1996 Sep; 17(1):13-22. PubMed ID: 8876671
[TBL] [Abstract][Full Text] [Related]
13. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies.
Sebti SM; Hamilton AD
Oncogene; 2000 Dec; 19(56):6584-93. PubMed ID: 11426643
[TBL] [Abstract][Full Text] [Related]
14. Upstream polybasic region in peptides enhances dual specificity for prenylation by both farnesyltransferase and geranylgeranyltransferase type I.
Hicks KA; Hartman HL; Fierke CA
Biochemistry; 2005 Nov; 44(46):15325-33. PubMed ID: 16285736
[TBL] [Abstract][Full Text] [Related]
15. Anticancer activity of farnesyltransferase and geranylgeranyltransferase I inhibitors: prospects for drug development.
Sebti SM; Hamilton AD
Expert Opin Investig Drugs; 1997 Nov; 6(11):1711-4. PubMed ID: 15989575
[TBL] [Abstract][Full Text] [Related]
16. Polylysine and CVIM sequences of K-RasB dictate specificity of prenylation and confer resistance to benzodiazepine peptidomimetic in vitro.
James GL; Goldstein JL; Brown MS
J Biol Chem; 1995 Mar; 270(11):6221-6. PubMed ID: 7890759
[TBL] [Abstract][Full Text] [Related]
17. Genetic studies on the functional relevance of the protein prenyltransferases in skin keratinocytes.
Lee R; Chang SY; Trinh H; Tu Y; White AC; Davies BS; Bergo MO; Fong LG; Lowry WE; Young SG
Hum Mol Genet; 2010 Apr; 19(8):1603-17. PubMed ID: 20106865
[TBL] [Abstract][Full Text] [Related]
18. Dominant negative alpha-subunit of farnesyl- and geranylgeranyl-transferase I inhibits insulin-induced differentiation of 3T3-L1 pre-adipocytes.
Solomon CS; Leitner JW; Goalstone ML
Int J Obes Relat Metab Disord; 2003 Jan; 27(1):40-7. PubMed ID: 12532152
[TBL] [Abstract][Full Text] [Related]
19. Restricted substrate specificity for the geranylgeranyltransferase-I enzyme in Cryptococcus neoformans: implications for virulence.
Selvig K; Ballou ER; Nichols CB; Alspaugh JA
Eukaryot Cell; 2013 Nov; 12(11):1462-71. PubMed ID: 24014765
[TBL] [Abstract][Full Text] [Related]
20. Amino acid residues that define both the isoprenoid and CAAX preferences of the Saccharomyces cerevisiae protein farnesyltransferase. Creating the perfect farnesyltransferase.
Caplin BE; Ohya Y; Marshall MS
J Biol Chem; 1998 Apr; 273(16):9472-9. PubMed ID: 9545274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
